Arantxa Sanz, CEO of Catalonia.health, participated in the European Health Summit in Brussels addressing how AI influences the interpretation of European health regulations. The study presented by LLYC reveals significant disparities in quality and access to information based on user profile and geography, emphasizing the need for reliable sources.

Catalonia.health, the association that brings together more than 240 companies and knowledge agents from across the health value chain in Catalonia, has opened the call for its annual awards. The awards, which will be announced during the Nit de Catalonia.health, recognise the career and outstanding contributions of one of the members of the ecosystem.

Catalonia.Health welcomes Marta Herrera as Head of Communications for the organisation. With this addition, we are strengthening our commitment to strategic communication in order to amplify the visibility and projection of the association's leadership, equipping ourselves with the capabilities to empower our community and ensure the impact of the valuable actions we generate together.

The technology centre Eurecat, a member of Catalonia.health, has received the IX National Congress of Entrepreneurial Scientists award for the development of a 3D-printed vascular stent.

The biotechnology company SpliceBio, a member of Catalonia.Health, has been selected as a finalist in several leading international awards in the life sciences sector. 

The life science venture capital Asabys, a member of Catalonia.health, has co-led a €37 million funding round for Qida, a provider of home-basedservices and products for senior well-being.

The pharmaceutical company Mitelos, a member of Catalonia.health, announced an exclusive licensing and distribution agreement with East Midlands Pharma (EM Pharma), a leading UK distributor of consumer health and OTC medical products.

The biopharmaceutical company ORYZON, a member of Catalonia.health, has announced that the first patient has been enrolled in RESTORE, its multi‑center,open‑label Phase Ib clinical trial of iadademstat in adults with sickle cell disease (SCD). 

Abzu, a member of Catalonia.health, and ADViRNA, a boutique U.S.-based CRO, are joining forces to develop novel siRNA therapeutics.

The venture capital company Asabys Partners, a member of Catalonia.health, and AltamarCAM  Partners, a global investment firm specialized in private markets, have reached an agreement to integrate Aliath Bioventures, a member of Catalonia.health, the life sciences team, into Asabys and to co-manage the Alta Life Sciences Spain I FCR fund.

The packaging company Miton, a member of Catalonia.health, has obtained international B Corp certification, a recognition that distinguishes companies that meet the highest standards of sustainability, social responsibility, and transparency, and that use business as a force for positive impact on society and the environment.

Vall  d'Hebron Research Institute (VHIR), a member of Catalonia.health, and Prous Institute for Biomedical Research have signed a three-year collaboration agreement to promote high-impact research projects that form part of or are in the selection phase of the VHIR's innovation portfolio.

The biotechnology company Inbiomotion, a member of Catalonia.health, has announced the publication, in the journal Journal of Medical Economics, of a study highlighting the positive economic impact of its diagnostic tool MAF Test® in patients with early-stage breast cancer.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced its participation as a sponsor of thefirst-ever Phelan-McDermid syndrome (PMS) burden of illness study. 

The venture capital company, Ysios Capital, a member of Catalonia.health, announced that its investee VarmX has signed a strategic development agreement with global biopharmaceutical company CSL (ASX:CSL), which includes an exclusive option to purchase the company.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced that it has been selected as a finalist in the 2025 European Lifestars  Awards in the category Post-IPO Raise of the Year for the European Mediterranean region.

The venture capital company Asabys Partners, a member of Catalonia.health, leads €10 million extension of its oversubscribed €35 million Series C financing round through its Sabadell Asabys II fund

The biotechnology company CONNECTA Therapeutics, a member of Catalonia.health, has announced the launch of studies for the paediatric development program of CTH120, an investigational FXS treatment, following positive results from the Phase I trial.

The biotech company Integra Therapeutics, a member of Catalonia.health, has announced it has closed a €10.7 million pre–Series A round of investment to advance the development of its FiCAT genetic editing platform and the preclinical validation of CAR-T therapies.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA), the European equivalent to an IND, to initiate a Phase Ib trial of iadademstat in sickle cell disease (SCD). This will be the first clinical trial investigating iadademstat in a non-malignant hematological indication.